Clearside Biomedical Inc (CLSD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clearside Biomedical Inc (CLSD) has a cash flow conversion efficiency ratio of 0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.48 Million) by net assets ($-53.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Clearside Biomedical Inc (CLSD) strategic asset index to assess the company's strategic physical and investment asset allocation.
Clearside Biomedical Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See CLSD net assets for net asset value and shareholders' equity analysis.
Clearside Biomedical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearside Biomedical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oryx International Growth Fund
LSE:OIG
|
0.003x |
|
GOLDREA RES CORP.
F:GOJ1
|
N/A |
|
Candela Invest SA
BR:CAND
|
0.050x |
|
Lucapa Diamond Co Ltd
F:NHY
|
-0.007x |
|
Thai Polycons Public Company Limited
BK:TPOLY
|
0.129x |
|
Rakovina Therapeutics Inc
V:RKV
|
-0.548x |
|
Keystone Law Group PLC
LSE:KEYS
|
0.375x |
|
MACDONALD MNS EXPL. A
F:3M7
|
N/A |
Annual Cash Flow Conversion Efficiency for Clearside Biomedical Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Clearside Biomedical Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see CLSD market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-38.85 Million | $-24.70 Million | 0.636x | -44.23% |
| 2023-12-31 | $-15.91 Million | $-18.14 Million | 1.140x | +190.45% |
| 2022-12-31 | $10.61 Million | $-13.37 Million | -1.260x | -345.81% |
| 2021-12-31 | $37.98 Million | $-10.73 Million | -0.283x | +81.12% |
| 2020-12-31 | $8.76 Million | $-13.12 Million | -1.497x | +38.29% |
| 2019-12-31 | $11.16 Million | $-27.07 Million | -2.426x | +27.65% |
| 2018-12-31 | $23.62 Million | $-79.20 Million | -3.353x | -40.57% |
| 2017-12-31 | $21.41 Million | $-51.08 Million | -2.385x | -652.72% |
| 2016-12-31 | $71.66 Million | $-22.71 Million | -0.317x | -183.57% |
| 2015-12-31 | $-36.66 Million | $-13.90 Million | 0.379x | -20.14% |
| 2014-12-31 | $-19.21 Million | $-9.12 Million | 0.475x | -25.44% |
| 2013-12-31 | $-10.74 Million | $-6.84 Million | 0.637x | +104.79% |
| 2012-12-31 | $239.00K | $-3.18 Million | -13.289x | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more